Merrimack Pharmaceuticals is focusing on advancing its oncology pipeline, particularly MM-398 for metastatic pancreatic cancer and MM-121 for various solid tumors.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.